Theravance Biopharma Inc
F:0TB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Theravance Biopharma Inc
F:0TB
|
KY |
Intrinsic Value
The intrinsic value of 
Theravance Biopharma Inc (0TB) under the Base Case is 12.22 EUR per share.
Compared with the current market price of 14.7 EUR, the stock appears
Overvalued by 17% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Theravance Biopharma Does
Theravance Biopharma is a biopharmaceutical company that develops and commercializes medicines for lung disease and certain serious infections. Its best-known products are treatments for chronic obstructive pulmonary disease and hospital or community bacterial infections, with a focus on patients who need inhaled or hospital-use therapies rather than broad primary-care drugs.
- Headquarters
- Cayman Islands KY
- Employees
- 90
- IPO date
- May 16, 2014
Revenue & Expenses Breakdown
Theravance Biopharma Inc
Earnings Waterfall
Theravance Biopharma Inc
The intrinsic value for Theravance Biopharma Inc (0TB) under the Base Case is 12.22 EUR.
Compared with the current market price of 14.7 EUR, the stock appears Overvalued by 17% .